Company Encyclopedia
View More
name
Iterum Therap
ITRM.US
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
4.346 T
ITRM.USMarket value -Rank by Market Cap -/-

Financial Score

18/11/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking155/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE285.48%A
    • Profit Margin-6913.08%E
    • Gross Margin94.87%A
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY11.76%C
    • Total Assets YoY104.11%A
    • Net Assets YoY35.86%A
  • Cash ScoreC
    • Cash Flow Margin-1.45%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreE
    • Gearing Ratio122.71%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Iterum Therapeutics’ Earnings Call: Optimism Amid Challenges

    Iterum Therapeutics' Q3 earnings call highlighted cautious optimism. The successful launch of Orlynda, a treatment for urinary tract infections, has shown strong initial market penetration. However, financial challenges persist with limited initial revenue, increased expenses, and a need for additional capital. The company plans to expand market access and raise funds to support growth, projecting 2026 revenue between $5 million and $15 million. Despite positive market feedback, financial hurdles remain a concern.

    Tip Ranks·
    US
    ITRM
    +8.12%
    Tip Ranks·
    US
    ITRM
    +8.12%

    Iterum Therap | 10-Q: FY2025 Q3 Revenue: USD 390 K

    LB filings·
    US
    ITRM
    +8.12%
    LB filings·
    US
    ITRM
    +8.12%

    Iterum Therap | 8-K: FY2025 Q3 Revenue: USD 390 K

    LB filings·
    US
    ITRM
    +8.12%
    LB filings·
    US
    ITRM
    +8.12%

    Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025

    DUBLIN, Ireland and CHICAGO, Nov. 07, 2025 ( GLOBE NEWSWIRE ) -- Iterum Therapeutics plc ( Nasdaq: ITRM ) ( Company ) , a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, ...

    GlobeNewswire·
    US
    ITRM
    +8.12%
    GlobeNewswire·
    US
    ITRM
    +8.12%

    Iterum Therapeutics Announces $20M Share Offering

    Iterum Therapeutics (ITRM) announced a $20 million share offering under its at-the-market agreement on October 16, 2025. The company has previously raised $36.2 million through similar offerings. Despite launching ORLYNVAH™ in the U.S. in August 2025, the company faces financial challenges, including ongoing net losses. Analysts rate ITRM as a Buy with a $5.00 price target, but Spark's AI Analyst considers it an Underperform due to weak market momentum and strategic uncertainties. Iterum's current market cap is $32.94 million.

    Tip Ranks·
    US
    ITRM
    +8.12%
    Tip Ranks·
    US
    ITRM
    +8.12%